The frontotemporal dementia-motor neuron disease continuum

The Lancet

Volumn 388, Issue 10047, 2016, Pages 919-931

  Burrell, James R ^a,b   Halliday, Glenda M ^a,b   Kril, Jillian J ^c   Ittner, Lars M ^a,b   Götz, Jürgen ^d   Kiernan, Matthew C ^a,c   Hodges, John R ^a,b  

^a NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDE; RNA BINDING PROTEIN; TAR DNA BINDING PROTEIN; C9ORF72 PROTEIN, HUMAN; DNA BINDING PROTEIN; NEUROPROTECTIVE AGENT; PROTEIN; REPETITIVE DNA; RILUZOLE; TDP-43 PROTEIN, HUMAN;

CHROMOSOME 9; CLINICAL FEATURE; DNA METHYLATION; EMOTION; EXECUTIVE FUNCTION; FRONTOTEMPORAL DEMENTIA; GENETICS; HUMAN; LANGUAGE; MOTOR NEURON DISEASE; NEUROIMAGING; OPEN READING FRAME; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SOCIAL COGNITION; BRAIN; COGNITION; DAILY LIFE ACTIVITY; IMAGE PROCESSING; METABOLISM; MUTATION; NEUROPSYCHOLOGICAL TEST; PATHOLOGY; PATIENT CARE; PROGNOSIS; PSYCHOLOGY;

ACTIVITIES OF DAILY LIVING; BRAIN; COGNITION; DNA METHYLATION; DNA REPEAT EXPANSION; DNA-BINDING PROTEINS; EXECUTIVE FUNCTION; FRONTOTEMPORAL DEMENTIA; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MOTOR NEURON DISEASE; MUTATION; NEUROIMAGING; NEUROPROTECTIVE AGENTS; NEUROPSYCHOLOGICAL TESTS; PATIENT CARE TEAM; PROGNOSIS; PROTEINS; RILUZOLE;

EID: 84988493699     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)00737-6     Document Type: Review

References (100)

1. 1 Neary, D, Snowden, JS, Mann, DM, Northen, B, Goulding, PJ, Macdermott, N, Frontal lobe dementia and motor neuron disease. J Neurol Neurosurg Psychiatry 53 (1990), 23–32.
2. 2 Stevens, M, van Duijn, CM, Kamphorst, W, et al. Familial aggregation in frontotemporal dementia. Neurology 50 (1998), 1541–1545.
3. 3 Vance, C, Al-Chalabi, A, Ruddy, D, et al. Familial amyotrophic lateral sclerosis with frontotemporal dementia is linked to a locus on chromosome 9p13.2-21.3. Brain 129 (2006), 868–876.
4. 4 DeJesus-Hernandez, M, Mackenzie, IR, Boeve, BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72 (2011), 245–256.
5. 5 Renton, AE, Majounie, E, Waite, A, et al., the ITALSGEN Consortium. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72 (2011), 257–268.
6. 6 Po, K, Leslie, FVC, Gracia, N, et al. Heritability in frontotemporal dementia: more missing pieces?. J Neurol 261 (2014), 2170–2177.
7. 7 van der Zee, J, Gijselinck, I, Dillen, L, et al., the European Early-Onset Dementia Consortium. A pan-European study of the C9orf72 repeat associated with FTLD: geographic prevalence, genomic instability, and intermediate repeats. Hum Mutat 34 (2013), 363–373.
8. 8 Devenney, E, Foxe, D, Dobson-Stone, C, Kwok, JB, Kiernan, MC, Hodges, JR, Clinical heterogeneity of the C9orf72 genetic mutation in frontotemporal dementia. Neurocase 20 (2014), 1–7.
9. 9 Irwin, DJ, McMillan, CT, Brettschneider, J, et al. Cognitive decline and reduced survival in C9orf72 expansion frontotemporal degeneration and amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 84 (2013), 163–169.
10. 10 Snowden, JS, Rollinson, S, Thompson, JC, et al. Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. Brain 135 (2012), 693–708.
11. 11 Cooper-Knock, J, Shaw, PJ, Kirby, J, The widening spectrum of C9ORF72-related disease; genotype/phenotype correlations and potential modifiers of clinical phenotype. Acta Neuropathol 127 (2014), 333–345.
12. 12 Lindquist, SG, Duno, M, Batbayli, M, et al. Corticobasal and ataxia syndromes widen the spectrum of C9ORF72 hexanucleotide expansion disease. Clin Genet 83 (2013), 279–283.
13. 13 Bieniek, KF, van Blitterswijk, M, Baker, MC, Petrucelli, L, Rademakers, R, Dickson, DW, Expanded C9ORF72 hexanucleotide repeat in depressive pseudodementia. JAMA Neurol 71 (2014), 775–781.
14. 14 van Blitterswijk, M, DeJesus-Hernandez, M, Niemantsverdriet, E, et al. Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. Lancet Neurol 12 (2013), 978–988.
15. 15 Xi, Z, Yunusova, Y, van Blitterswijk, M, et al. Identical twins with the C9orf72 repeat expansion are discordant for ALS. Neurology 83 (2014), 1476–1478.
16. 16 van Blitterswijk, M, van Es, MA, Hennekam, EAM, et al. Evidence for an oligogenic basis of amyotrophic lateral sclerosis. Hum Mol Genet 21 (2012), 3776–3784.
17. 17 Hardy, J, Rogaeva, E, Motor neuron disease and frontotemporal dementia: sometimes related, sometimes not. Exp Neurol 262 (2014), 75–83.
18. 18 Al-Chalabi, A, Hardiman, O, The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol 9 (2013), 617–628.
19. 19 Benatar, M, Wuu, J, Fernandez, C, et al. Motor neuron involvement in multisystem proteinopathy: implications for ALS. Neurology 80 (2013), 1874–1880.
20. 20 Canosa, A, Calvo, A, Moglia, C, et al. A familial ALS case carrying a novel p.G147C SOD1 heterozygous missense mutation with non-executive cognitive impairment. J Neurol Neurosurg Psychiatry 85 (2014), 1437–1439.
21. 21 Blair, IP, Williams, KL, Warraich, ST, et al. FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis. J Neurol Neurosurg Psychiatry 81 (2010), 639–645.
22. 22 Rohrer, JD, Guerreiro, R, Vandrovcova, J, et al. The heritability and genetics of frontotemporal lobar degeneration. Neurology 73 (2009), 1451–1456.
23. 23 Benajiba, L, Le Ber, I, Camuzat, A, et al., the French Clinical and Genetic Research Network on Frontotemporal Lobar Degeneration/Frontotemporal Lobar Degeneration with Motoneuron Disease. TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration. Ann Neurol 65 (2009), 470–473.
24. 24 Sareen, D, O'Rourke, JG, Meera, P, et al. Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci Transl Med, 5, 2013, 208ra149.
25. 25 Akimoto, C, Volk, AE, van Blitterswijk, M, et al. A blinded international study on the reliability of genetic testing for GGGGCC-repeat expansions in C9orf72 reveals marked differences in results among 14 laboratories. J Med Genet 51 (2014), 419–424.
26. 26 Levine, TP, Daniels, RD, Gatta, AT, Wong, LH, Hayes, MJ, The product of C9orf72, a gene strongly implicated in neurodegeneration, is structurally related to DENN Rab-GEFs. Bioinformatics 29 (2013), 499–503.
27. 27 Gijselinck, I, Van Langenhove, T, van der Zee, J, et al. A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. Lancet Neurol 11 (2012), 54–65.
28. 28 Donnelly, CJ, Zhang, P-W, Pham, JT, et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron 80 (2013), 415–428.
29. 29 Almeida, S, Gascon, E, Tran, H, et al. Modeling key pathological features of frontotemporal dementia with C9ORF72 repeat expansion in iPSC-derived human neurons. Acta Neuropathol 126 (2013), 385–399.
30. 30 Waite, AJ, Bäumer, D, East, S, et al. Reduced C9orf72 protein levels in frontal cortex of amyotrophic lateral sclerosis and frontotemporal degeneration brain with the C9ORF72 hexanucleotide repeat expansion. Neurobiol Aging 35 (2014), e5–1779.
31. 31 Harms, MB, Cady, J, Zaidman, C, et al. Lack of C9ORF72 coding mutations supports a gain of function for repeat expansions in amyotrophic lateral sclerosis. Neurobiol Aging, 34, 2013, 2234.
32. 32 Zhang, D, Iyer, LM, He, F, Aravind, L, Discovery of novel DENN proteins: implications for the evolution of eukaryotic intracellular membrane structures and human disease. Front Genet, 3, 2012, 283.
33. 33 Carrasquillo, MM, Nicholson, AM, Finch, N, et al. Genome-wide screen identifies rs646776 near sortilin as a regulator of progranulin levels in human plasma. Am J Hum Genet 87 (2010), 890–897.
34. 34 Ciura, S, Lattante, S, Le Ber, I, et al. Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral sclerosis. Ann Neurol 74 (2013), 180–187.
35. 35 Therrien, M, Rouleau, GA, Dion, PA, Parker, JA, Deletion of C9ORF72 results in motor neuron degeneration and stress sensitivity in C. elegans. PLoS One, 8, 2013, e83450.
36. 36 Lagier-Tourenne, C, Baughn, M, Rigo, F, et al. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc Natl Acad Sci USA 110 (2013), E4530–E4539.
37. 37 Zu, T, Liu, Y, Bañez-Coronel, M, et al. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc Natl Acad Sci USA 110 (2013), e4968–e4977.
38. 38 Gendron, TF, Bieniek, KF, Zhang, Y-J, et al. Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS. Acta Neuropathol 126 (2013), 829–844.
39. 39 Ash, PEA, Bieniek, KF, Gendron, TF, et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron 77 (2013), 639–646.
40. 40 Liu, EY, Russ, J, Wu, K, et al. C9orf72 hypermethylation protects against repeat expansion-associated pathology in ALS/FTD. Acta Neuropathol 128 (2014), 525–541.
41. 41 Xi, Z, Zinman, L, Moreno, D, et al. Hypermethylation of the CpG island near the G4C2 repeat in ALS with a C9orf72 expansion. Am J Hum Genet 92 (2013), 981–989.
42. 42 Belzil, VV, Bauer, PO, Prudencio, M, et al. Reduced C9orf72 gene expression in c9FTD/ALS is caused by histone trimethylation, an epigenetic event detectable in blood. Acta Neuropathol 126 (2013), 895–905.
43. 43 Russ, J, Liu, EY, Wu, K, et al. Hypermethylation of repeat expanded C9orf72 is a clinical and molecular disease modifier. Acta Neuropathol 129 (2015), 39–52.
44. 44 Neumann, M, Sampathu, DM, Kwong, LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314 (2006), 130–133.
45. 45 Chare, L, Hodges, JR, Leyton, CE, et al. New criteria for frontotemporal dementia syndromes: clinical and pathological diagnostic implications. J Neurol Neurosurg Psychiatry 85 (2014), 865–870.
46. 46 Tan, RH, Shepherd, CE, Kril, JJ, et al. Classification of FTLD-TDP cases into pathological subtypes using antibodies against phosphorylated and non-phosphorylated TDP43. Acta Neuropathol Commun, 1, 2013, 33.
47. 47 Mackenzie, IR, Rademakers, R, Neumann, M, TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol 9 (2010), 995–1007.
48. 48 Tan, RH, Wong, S, Kril, JJ, et al. Beyond the temporal pole: limbic memory circuit in the semantic variant of primary progressive aphasia. Brain 137 (2014), 2065–2076.
49. 49 Arai, T, Significance and limitation of the pathological classification of TDP-43 proteinopathy. Neuropathology 34 (2014), 578–588.
50. 50 Mackenzie, IRA, Frick, P, Neumann, M, The neuropathology associated with repeat expansions in the C9ORF72 gene. Acta Neuropathol 127 (2014), 347–357.
51. 51 Brettschneider, J, Del Tredici, K, Irwin, DJ, et al. Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bv FTD). Acta Neuropathol 127 (2014), 423–439.
52. 52 Brettschneider, J, Del Tredici, K, Toledo, JB, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol 74 (2013), 20–38.
53. 53 Braak, H, Ludolph, A, Thal, DR, Del Tredici, K, Amyotrophic lateral sclerosis: dash-like accumulation of phosphorylated TDP-43 in somatodendritic and axonal compartments of somatomotor neurons of the lower brainstem and spinal cord. Acta Neuropathol 120 (2010), 67–74.
54. 54 Kersaitis, C, Halliday, GM, Xuereb, JH, et al. Ubiquitin-positive inclusions and progression of pathology in frontotemporal dementia and motor neurone disease identifies a group with mainly early pathology. Neuropathol Appl Neurobiol 32 (2006), 83–91.
55. 55 Braak, H, Brettschneider, J, Ludolph, AC, Lee, VM, Trojanowski, JQ, Del Tredici, K, Amyotrophic lateral sclerosis—a model of corticofugal axonal spread. Nat Rev Neurol 9 (2013), 708–714.
56. 56 Cooper-Knock, J, Hewitt, C, Highley, JR, et al. Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72. Brain 135 (2012), 751–764.
57. 57 Phukan, J, Elamin, M, Bede, P, et al. The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatry 83 (2012), 102–108.
58. 58 Montuschi, A, Iazzolino, B, Calvo, A, et al. Cognitive correlates in amyotrophic lateral sclerosis: a population-based study in Italy. J Neurol Neurosurg Psychiatry 86 (2015), 168–173.
59. 59 Elamin, M, Bede, P, Byrne, S, et al. Cognitive changes predict functional decline in ALS: a population-based longitudinal study. Neurology 80 (2013), 1590–1597.
60. 60 Woolley, SC, York, MK, Moore, DH, et al. Detecting frontotemporal dysfunction in ALS: utility of the ALS Cognitive Behavioral Screen (ALS-CBS). Amyotroph Lateral Scler 11 (2010), 303–311.
61. 61 Raaphorst, J, Beeldman, E, Schmand, B, et al. The ALS-FTD-Q: a new screening tool for behavioral disturbances in ALS. Neurology 79 (2012), 1377–1383.
62. 62 Mioshi, E, Hsieh, S, Caga, J, et al. A novel tool to detect behavioural symptoms in ALS. Amyotroph Lateral Scler Frontotemporal Degener 15 (2014), 298–304.
63. 63 Burrell, JR, Kiernan, MC, Vucic, S, Hodges, JR, Motor neuron dysfunction in frontotemporal dementia. Brain 134 (2011), 2582–2594.
64. 64 Josephs, KA, Parisi, JE, Knopman, DS, Boeve, BF, Petersen, RC, Dickson, DW, Clinically undetected motor neuron disease in pathologically proven frontotemporal lobar degeneration with motor neuron disease. Arch Neurol 63 (2006), 506–512.
65. 65 Abrahams, S, Goldstein, LH, Al-Chalabi, A, et al. Relation between cognitive dysfunction and pseudobulbar palsy in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 62 (1997), 464–472.
66. 66 Stukovnik, V, Zidar, J, Podnar, S, Repovs, G, Amyotrophic lateral sclerosis patients show executive impairments on standard neuropsychological measures and an ecologically valid motor-free test of executive functions. J Clin Exp Neuropsychol 32 (2010), 1095–1109.
67. 67 Taylor, LJ, Brown, RG, Tsermentseli, S, et al. Is language impairment more common than executive dysfunction in amyotrophic lateral sclerosis?. J Neurol Neurosurg Psychiatry 84 (2013), 494–498.
68. 68 Abrahams, S, Leigh, PN, Goldstein, LH, Cognitive change in ALS: a prospective study. Neurology 64 (2005), 1222–1226.
69. 69 Bak, TH, O'Donovan, DG, Xuereb, JH, Boniface, S, Hodges, JR, Selective impairment of verb processing associated with pathological changes in Brodmann areas 44 and 45 in the motor neurone disease-dementia-aphasia syndrome. Brain 124 (2001), 103–120.
70. 70 Abrahams, S, Social cognition in amyotrophic lateral sclerosis. Neurodegener Dis Manag 1 (2011), 397–405.
71. 71 Meier, SL, Charleston, AJ, Tippett, LJ, Cognitive and behavioural deficits associated with the orbitomedial prefrontal cortex in amyotrophic lateral sclerosis. Brain 133 (2010), 3444–3457.
72. 72 Zimmerman, EK, Eslinger, PJ, Simmons, Z, Barrett, AM, Emotional perception deficits in amyotrophic lateral sclerosis. Cogn Behav Neurol 20 (2007), 79–82.
73. 73 Girardi, A, Macpherson, SE, Abrahams, S, Deficits in emotional and social cognition in amyotrophic lateral sclerosis. Neuropsychology 25 (2011), 53–65.
74. 74 Cavallo, M, Adenzato, M, Macpherson, SE, Karwig, G, Enrici, I, Abrahams, S, Evidence of social understanding impairment in patients with amyotrophic lateral sclerosis. PLoS One, 6, 2011, e25948.
75. 75 Lulé, D, Kurt, A, Jürgens, R, et al. Emotional responding in amyotrophic lateral sclerosis. J Neurol 252 (2005), 1517–1524.
76. 76 Cerami, C, Dodich, A, Canessa, N, et al. Emotional empathy in amyotrophic lateral sclerosis: a behavioural and voxel-based morphometry study. Amyotroph Lateral Scler Frontotemporal Degener 15 (2014), 21–29.
77. 77 Lomen-Hoerth, C, Murphy, J, Langmore, S, Kramer, JH, Olney, RK, Miller, B, Are amyotrophic lateral sclerosis patients cognitively normal?. Neurology 60 (2003), 1094–1097.
78. 78 Mioshi, E, Caga, J, Lillo, P, et al. Neuropsychiatric changes precede classic motor symptoms in ALS and do not affect survival. Neurology 82 (2014), 149–155.
79. 79 Lillo, P, Mioshi, E, Hodges, JR, Caregiver burden in amyotrophic lateral sclerosis is more dependent on patients' behavioral changes than physical disability: a comparative study. BMC Neurol, 12, 2012, 156.
80. 80 Lillo, P, Garcin, B, Hornberger, M, Bak, TH, Hodges, JR, Neurobehavioral features in frontotemporal dementia with amyotrophic lateral sclerosis. Arch Neurol 67 (2010), 826–830.
81. 81 Devenney, E, Hornberger, M, Irish, M, et al. Frontotemporal dementia associated with the C9ORF72 mutation: a unique clinical profile. JAMA Neurol 71 (2014), 331–339.
82. 82 Bede, P, Hardiman, O, Lessons of ALS imaging: pitfalls and future directions—a critical review. Neuroimage Clin 4 (2014), 436–443.
83. 83 Lillo, P, Mioshi, E, Burrell, JR, Kiernan, MC, Hodges, JR, Hornberger, M, Grey and white matter changes across the amyotrophic lateral sclerosis-frontotemporal dementia continuum. PLoS One, 7, 2012, e43993.
84. 84 Fekete, T, Zach, N, Mujica-Parodi, LR, Turner, MR, Multiple kernel learning captures a systems-level functional connectivity biomarker signature in amyotrophic lateral sclerosis. PLoS One, 8, 2013, e85190.
85. 85 Agosta, F, Canu, E, Valsasina, P, et al. Divergent brain network connectivity in amyotrophic lateral sclerosis. Neurobiol Aging 34 (2013), 419–427.
86. 86 Agosta, F, Sala, S, Valsasina, P, et al. Brain network connectivity assessed using graph theory in frontotemporal dementia. Neurology 81 (2013), 134–143.
87. 87 Bede, P, Bokde, ALW, Byrne, S, et al. Multiparametric MRI study of ALS stratified for the C9orf72 genotype. Neurology 81 (2013), 361–369.
88. 88 Cistaro, A, Pagani, M, Montuschi, A, et al. The metabolic signature of C9ORF72-related ALS: FDG PET comparison with nonmutated patients. Eur J Nucl Med Mol Imaging 41 (2014), 844–852.
89. 89 Lee, SE, Khazenzon, AM, Trujillo, AJ, et al. Altered network connectivity in frontotemporal dementia with C9orf72 hexanucleotide repeat expansion. Brain 137 (2014), 3047–3060.
90. 90 Turner, MR, Kiernan, MC, Leigh, PN, Talbot, K, Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol 8 (2009), 94–109.
91. 91 Strong, MJ, Grace, GM, Freedman, M, et al. Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 10 (2009), 131–146.
92. 92 Abrahams, S, Newton, J, Niven, E, Foley, J, Bak, TH, Screening for cognition and behaviour changes in ALS. Amyotroph Lateral Scler Frontotemporal Degener 15 (2014), 9–14.
93. 93 Goldstein, LH, Abrahams, S, Changes in cognition and behaviour in amyotrophic lateral sclerosis: nature of impairment and implications for assessment. Lancet Neurol 12 (2013), 368–380.
94. 94 McCluskey, L, Vandriel, S, Elman, L, et al. ALS-Plus syndrome: non-pyramidal features in a large ALS cohort. J Neurol Sci 345 (2014), 118–124.
95. 95 Pupillo, E, Messina, P, Logroscino, G, Beghi, E, the SLALOM Group. Long-term survival in amyotrophic lateral sclerosis: a population-based study. Ann Neurol 75 (2014), 287–297.
96. 96 Wood, EM, Falcone, D, Suh, E, et al. Development and validation of pedigree classification criteria for frontotemporal lobar degeneration. JAMA Neurol 70 (2013), 1411–1417.
97. 97 Miller, RG, Jackson, CE, Kasarskis, EJ, et al., the Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 73 (2009), 1227–1233.
98. 98 Kiernan, MC, Vucic, S, Cheah, BC, et al. Amyotrophic lateral sclerosis. Lancet 377 (2011), 942–955.
99. 99 Limousin, N, Blasco, H, Corcia, P, et al. Malnutrition at the time of diagnosis is associated with a shorter disease duration in ALS. J Neurol Sci 297 (2010), 36–39.
100. 100 Ahmed, RM, Mioshi, E, Caga, J, et al. Body mass index delineates ALS from FTD: implications for metabolic health. J Neurol 261 (2014), 1774–1780.